Aerosolized Granulocyte-Macrophage Colony Stimulating Factor (Sargramostim) in Combination With Anti-PD1 Therapy for the Treatment of Metastatic Melanoma to the Lung
Latest Information Update: 25 Nov 2024
At a glance
- Drugs Nivolumab (Primary) ; Sargramostim (Primary)
- Indications Cancer metastases; Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 21 Nov 2024 Planned number of patients changed from 24 to 20.
- 21 Nov 2024 Planned End Date changed from 1 Jul 2025 to 28 Jan 2026.
- 21 Nov 2024 Planned primary completion date changed from 1 Jul 2025 to 28 Jan 2026.